Amy K Barczak
Overview
Explore the profile of Amy K Barczak including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
46
Citations
2057
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tsolaki A, Barczak A, Kishore U
Front Mol Med
. 2025 Mar;
5:1568256.
PMID: 40041454
No abstract available.
2.
Zunt J, Barczak A, Chang D
N Engl J Med
. 2025 Feb;
392(7):699-709.
PMID: 39938097
No abstract available.
3.
Phan T, Ribeiro R, Edelstein G, Boucau J, Uddin R, Marino C, et al.
J Virol
. 2025 Feb;
:e0162324.
PMID: 39902924
Importance: Nirmatrelvir-ritonavir is an effective treatment for SARS-CoV-2. In a subset of individuals treated with nirmatrelvir-ritonavir, the initial reduction in viral load is followed by viral rebound once treatment is...
4.
Jani C, Jain N, Marsh A, Uchil P, Doan T, Hudspith M, et al.
Sci Adv
. 2025 Jan;
11(5):eadr6166.
PMID: 39888996
(Mtb) has evolved to be exquisitely adapted to survive within host macrophages. The capacity to damage the phagosomal membrane has emerged as central to Mtb virulence. While Mtb factors driving...
5.
Phan T, Ribeiro R, Edelstein G, Boucau J, Uddin R, Marino C, et al.
bioRxiv
. 2024 Sep;
PMID: 39345409
In a subset of SARS-CoV-2 infected individuals treated with the oral antiviral nirmatrelvir-ritonavir, the virus rebounds following treatment. The mechanisms driving this rebound are not well understood. We used a...
6.
Tamura T, Choudhary M, Deo R, Yousuf F, Gomez A, Edelstein G, et al.
JAMA Netw Open
. 2024 Sep;
7(9):e2435431.
PMID: 39320890
Importance: Previous studies have identified mutations in SARS-CoV-2 strains that confer resistance to nirmatrelvir, yet how often this resistance arises and its association with posttreatment virologic rebound is not well...
7.
Auld S, Barczak A, Bishai W, Coussens A, Dewi I, Mitini-Nkhoma S, et al.
Am J Respir Crit Care Med
. 2024 Aug;
210(8):979-993.
PMID: 39141569
Post-tuberculosis (post-TB) lung disease is increasingly recognized as a major contributor to the global burden of chronic lung disease, with recent estimates indicating that over half of TB survivors have...
8.
Auld S, Sheshadri A, Alexander-Brett J, Aschner Y, Barczak A, Basil M, et al.
Ann Am Thorac Soc
. 2024 Jul;
21(9):1219-1237.
PMID: 39051991
Continued improvements in the treatment of pulmonary infections have paradoxically resulted in a growing challenge of individuals with postinfectious pulmonary complications (PIPCs). PIPCs have been long recognized after tuberculosis, but...
9.
Boucau J, Naidoo T, Liu Y, Dasgupta S, Jain N, Castillo J, et al.
bioRxiv
. 2024 Jun;
PMID: 38895338
Post-TB lung disease (PTLD) causes a significant burden of global disease. Fibrosis is a central component of many clinical features of PTLD. To date, we have a limited understanding of...
10.
Ogunlade B, Tadesse L, Li H, Vu N, Banaei N, Barczak A, et al.
Proc Natl Acad Sci U S A
. 2024 Jun;
121(25):e2315670121.
PMID: 38861604
Tuberculosis (TB) is the world's deadliest infectious disease, with over 1.5 million deaths and 10 million new cases reported anually. The causative organism (Mtb) can take nearly 40 d to...